What is HC Wainwright's Estimate for Savara FY2026 Earnings?

Savara Inc (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Savara in a research report issued to clients and investors on Wednesday, May 28th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.45) per share for the year, down from their previous forecast of ($0.42). HC Wainwright has a "Neutral" rating and a $2.00 price objective on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara's FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.12) EPS.

A number of other equities research analysts also recently issued reports on the company. Evercore ISI lowered their price target on Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. Guggenheim reissued a "buy" rating and set a $8.00 target price (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Finally, Wells Fargo & Company cut their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.17.

Savara Price Performance

Shares of SVRA stock remained flat at $2.40 on Monday. The stock had a trading volume of 1,097,667 shares, compared to its average volume of 1,427,066. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $414.81 million, a PE ratio of -5.58 and a beta of 0.44. The stock's fifty day moving average price is $2.91 and its 200 day moving average price is $2.94. Savara has a 1-year low of $1.89 and a 1-year high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12).

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bain Capital Life Sciences Investors LLC raised its stake in shares of Savara by 20.8% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company's stock valued at $48,754,000 after purchasing an additional 3,035,164 shares during the period. Frazier Life Sciences Management L.P. grew its holdings in Savara by 32.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company's stock valued at $31,751,000 after purchasing an additional 2,801,922 shares in the last quarter. Vestal Point Capital LP increased its stake in Savara by 2.1% during the 1st quarter. Vestal Point Capital LP now owns 11,000,000 shares of the company's stock worth $30,470,000 after buying an additional 225,000 shares during the period. Vanguard Group Inc. lifted its holdings in Savara by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock worth $25,512,000 after buying an additional 365,959 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its position in Savara by 7.3% in the 1st quarter. Nantahala Capital Management LLC now owns 8,075,375 shares of the company's stock valued at $22,369,000 after buying an additional 550,116 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.